Trial Profile
An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Mosunetuzumab (Primary) ; Mosunetuzumab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Genentech
- 01 Apr 2024 Interim safety results published in the Clinical Lymphoma, Myeloma & Leukemia
- 09 Feb 2024 According to a Chugai Pharmaceutical media release, based on this phase I/II and phase I study conducted in Japan the company plans to apply for approval in Japan.
- 03 Feb 2024 Planned End Date changed from 15 Nov 2023 to 15 Nov 2025.